Real-world disease, patient characteristics and treatment patterns in patients with Non-Small Cell Lung Cancer and extensive stage Small cell lung cancer in Belgium [AIBED]

Study identification

• EU PAS number:
  EUPAS1000000396
• Study ID:
  1000000396
• Official title and acronym:
  Real-world disease, patient characteristics and treatment patterns in patients with Non-Small Cell Lung Cancer and extensive stage Small cell lung cancer in Belgium [AIBED]
• DARWIN EU® study:
  No
• Study countries:
  Belgium
• Study description:
  This multicenter study describes demographics, biomarker testing, and treatment patterns in Belgian patients with lung cancer by leveraging natural language processing and the OMOP common data model.
• Study status:
  Finalised

Research institutions and networks

Institutions

AZ Maria Middelares General Hospital

Belgium

AstraZeneca

Universitair Ziekenhuis Antwerpen (UZA)

Belgium

Universitair Ziekenhuis Brussel Algemeen Ziekenhuis Groeninge Universitair Ziekenhuis Leuven LynxCare Clinical Informatics

Study timelines

Date when funding contract was signed

Actual:02/12/2019

Study start date

Actual:01/10/2023

Date of final study report

Planned:31/05/2022

Actual:28/06/2024

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

AstraZeneca BeLux

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable